Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3

Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu · 2025

Read Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3 by Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-05608.txt.

Introduction

Austin Morris and co-authors design a compact accelerator to make a cancer treatment isotope without a reactor, in work from twenty twenty-five. The isotope, lutetium-177, is used in approved targeted radiation drugs. Reactor supply is the norm, so a small machine source could widen access.

Their plan fires deuterons at an enriched ytterbium oxide target with a linear accelerator about twelve metres long. Lab and simulated yield curves feed the output math. A five day run could make more than a milligram of the isotope at high activity. After two days of processing, purity passes a high bar with no carrier added. The authors call the route viable for clinical use.

Catalog record

CREATORAustin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2503-05608

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3 Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu Abstract We use experimental and simulated excitation functions to estimate the yield of deuteron activations on a [ 176 Yb]Yb 2 O 3 target enriched to 99%. Subsequent calculations are used to determine the production of radiotherapeutic 177 Lu according to a 10 mA, 18 MeV D + D^{+} compact linear accelerator. The design comprises a single radio-frequency quadrupole accelerator (RFQ) and seven drift tube linacs (DTLs) that achieve a beam efficiency of 98.5% over a length of 12 ​ m 12\,\text{m} . Our results show that a 5-day irradiation can yield more than 1 1 mg of 177 Lu, exceeding 4.4 4.4 TBq. After a 2 day processing period, it is estimated that the sample will have a radiopurity greater than 99.8% (carrier-free). Given recent EMA and FDA approvals of 177 Lu-DOTATATE and 177 Lu-PSMA-617, our results confirm the viability of accelerator-based 177 Lu production and provide a promising clinical alternative to reactor-based methods. Preprint: APS/123-QED I Introduction Several studies have reported on the potential of 177 Lu as an in vivo radioisotope useful for the treatment of metastatic lesions and neuroendocrine cancers [ 1 , 2 , 3 ] . 177 Lu is a desirable radioisotope due to its intermediate half-life ( t_{1/2} = 6.65 days) and moderate energy release. It beta decays to a stable ground state of 177 Hf (78.6% of the time), to a 0.25 MeV excited state (9.2%), and to a 0.32 MeV excited state (12.2%). Compared to other therapeutic radioisotopes (such as 90 Y, 131 I, and 186 Re), the localized beta particles produced by 177 Lu have a smaller mean penetration range in tissue of approximately 0.62\,\text{mm} [ 4 ] . Since the excited states also produce low-energy gamma rays—113 keV (6.6%) and 208 keV (11%)—PET image-guided, theranostic (therapy and diagnosis) treatments are possible [ 5 , 6 , 7 , 8 ] . Furthermore, 177 Lu can be combined with other radionuclides, such as 67 Cu and 90 Y, for tandem use [ 9 ] . For targeted radiotherapy, lutetium can be added to a variety of molecular carriers, antibodies, and peptides to preferentially accumulate in cell receptors over expressed on tumor surfaces [ 1 , 6 , 10 ] . Examples include prostrate-specific membrane antigen (PSMA) and peptide receptor radionuclide therapy (PRRT). An amino acid transporter protein, PSMA is expressed 100 to 1000 times more in prostate cancer than in normal tissue [ 11 , 4 , 12 , 13 , 14 ] . Successful treatments of patients with metastatic lesions and prostrate cancer have led to recent approval by the EMA and FDA of 177 Lu-DOTATATE and 177 Lu-PSMA-617 for neuroendocrine cancers and PSMA-positive metastatic castration-resistant prostrate cancer (mCRPR) [ 9 , 15 , 10 , 16 , 11 , 12 , 17 , 18 , 19 ] . Early results indicate that 177 Lu-based drugs have limited side effects and a better toxicity profile compared to other radionuclides [ 13 , 17 , 14 ] . Consequently, the demand for 177 Lu has increased in recent years, with a particular focus on developing production facilities that are better equipped to meet treatment requirements. In this study, we present the general design of an 18 MeV D^{+} linear accelerator (linac) optimized for the production of high purity 177 Lu. We develop a model based on experimental [ 2 , 20 , 21 ] and simulated [ 22 ] excitation functions to optimize the target width and yield of deuteron activations from a Yb 2 O 3 target enriched to 99% 176 Yb. Based on our accelerator and target parameters, the expected radiopurity of carrier-free 177 Lu is estimated to exceed 99.8% after a 5-day irradiation. Longer irradiations offer similar radiopurity and produce 1 to 2 mg of 177 Lu. Compared to previous studies using reactor-based production, we show that accelerator-based production generates less target burn-up, reduced waste, higher radiopurity, and competitive overall yield. Since an accelerator facility is generally safer and easier to maintain than a high flux reactor, the design is expected to better meet therapeutic production demand. II Accelerator Design Currently, 177 Lu is most commonly produced by neutron activation in a high flux reactor [ 1 , 23 ] . This involves either irradiating an ordinary lutetium target or an enriched 176 Yb target (12.9% natural abundance), giving the reactions {}^{176}\text{Lu}\,+\,n\, \displaystyle\longrightarrow \,{}^{177}\text{Lu}\,+\,{\gamma}\;\;\text{(direct),} (1) {}^{176}\text{Yb}\,+\,n\, \displaystyle\longrightarrow \,{}^{177}\text{Yb}\,+\,\gamma\;\;\text{(indirect)}. (2) In the indirect route, 177 Yb ( t_{1/2} = 1.91 h) is produced, which quickly beta-decays into 177 Lu. The drawbacks of reactor-based production include the high thermal neutron flux required ( 10^{14} n/cm 2 /s) as well as the 2.6% natural abundance of 176 Lu ( t_{1/2}\sim 4\times 10^{10} y). For both direct and indirect production routes, high neutron activation cross sections lead to significant target burn-up and radioactive waste, which also reduces the specific activity of 177 Lu [ 16 , 24 ] . The waste products include {}^{174\text{g}} Lu ( t_{1/2}=3.31 y), {}^{174\text{m}} Lu ( t_{1/2}=120.9 d), {}^{176\text{m}} Lu ( t_{1/2}=3.66 d), and {}^{177\text{m}} Lu ( t_{1/2}=160.4 d) [ 25 ] . Due to these contaminants, target waste and patient urine must be disposed of in a dedicated waste management facility [ 5 ] . Large amounts of stable 175 Lu in the target also reduce the specific activity of the desired 177 Lu product. By comparison, accelerator-based production methods generate one-tenth as much nuclear waste, require lower maintenance costs (including decommissioning), and have a better safety profile [ 26 ] . Proton beams are inadequate for lutetium production as a result of small Yb/Lu activation cross sections. However, deuteron beams, with moderate stopping power and high neutron-stripping cross sections, provide an ideal choice [ 27 ] . Similar to before, 177 Lu is produced indirectly by deuterons through {}^{176}\text{Yb}\,+\,d\, \displaystyle\longrightarrow \,{}^{177}\text{Yb}\,+\,p\;\;(Q=3.34\text{ MeV}) (3) reactions, at a rate about nine times greater than for direct 176 Yb( d,n ) 177 Lu reactions [ 28 ] . The 176 Yb( d,p ) 177 Yb cross section begins to increase around 5 MeV before reaching a peak of approximately 230 mb at 12.5 MeV, as shown in Figure 1 . Figure 1: Experimental [ 2 , 20 , 21 , 29 ] and simulated [ 25 ] 176 Yb( d,p ) 177 Yb cross section data. Due to the large underestimation by TENDL-2023 for this reaction, we instead use an interpolation of the Hermanne (2006) and Manenti (2010) data for subsequent calculations. For higher deuteron energies, 174g+m Lu production cross sections increase [ 9 ] . Hence, a higher purity of 177 Lu is obtained for deuteron beam energies E<20 MeV [ 2 ] . In this range, metastable 176m Lu is produced but decays rapidly, while the production of longer-lived 177m Lu is negligible due to its high spin value J^{\pi}=23/2^{-} [ 30 ] . Figure 2: Side-view schematic of the RFQ-DTL components, including water cooling ports, vacuum pumps, power couplers, and tuners. Labels correspond to: (1) microwave waveguide, (2) ECR (Electron Cyclotron

Read the complete text